Neuren Pharmaceuticals hopes to develop long-term treatment for newborn brain injury
Subscribe to BusinessDesk
Stay informed on business, government and financial developments across New Zealand.
- Deeply researched, twice-edited and fact-checked news
- Annual subscribers also receive a complimentary subscription to The Wall Street Journal
- Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers
You can cancel anytime with two clicks, an email or a phone call.
Find out more.
We are serious about journalism.
Already a Subscriber ? Sign in here.
All subscriptions auto renew but are easy to cancel.
Total Price Including Tax: {{ priceWithTax(selectedPlan) | currency }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerSeat ? '/ '+ spark.seatName : '' }} {{ selectedPlan.type == 'user' && spark.chargesUsersPerTeam ? '/ '+ __('teams.team') : '' }} / {{ __(selectedPlan.interval) | capitalize }}
Not convinced yet?
Subscribe to our free 7am Headlines newsletter.
A quick summary of everything BusinessDesk has published in the previous 24 hours. No BusinessDesk
subscription needed.
NZX 50 dips despite Fletcher Building's 4.6% gain
Pacific Edge shares gained after it said it got a step closer to Medicare approval.
First look at NZICC, and SkyCity's hopes for $70m fund
SkyCity's COO says a new govt fund should help fill empty hotel rooms across Auckland.
Future leaders start by Dreaming Big
How OnBeingBold empowers Year 13 girls at free leadership events.
Free AI training blitz targets 10,000 Kiwis
Workshops aim to close NZ’s AI skills gap and boost productivity – no tech skills required.
